Lenvatinib Plus Camrelizumab versus Lenvatinib Monotherapy as Post-Progression Treatment for Advanced Hepatocellular Carcinoma: A Short-Term Prognostic Study

OBJECTIVE: Compared the outcomes between lenvatinib plus camrelizumab therapy and lenvatinib monotherapy as post-progression treatment for advanced hepatocellular carcinoma (HCC) with progressive disease (PD). PATIENTS AND METHODS: A total of 48 advanced HCC patients were included in this retrospect...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Fuqun, Huang, Qizhen, He, Jian, Luo, Liuping, Zeng, Yongyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8166816/
https://www.ncbi.nlm.nih.gov/pubmed/34079375
http://dx.doi.org/10.2147/CMAR.S304820

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8166816/
https://www.ncbi.nlm.nih.gov/pubmed/34079375
http://dx.doi.org/10.2147/CMAR.S304820

Ejemplares similares